Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Intrarenal Complement System Transcripts in Chronic Antibody-Mediated Rejection and Recurrent IgA Nephropathy in Kidney Transplantation

M. Cernoch, P. Hruba, M. Kollar, P. Mrazova, L. Stranavova, A. Lodererova, E. Honsova, O. Viklicky,

. 2018 ; 9 (-) : 2310. [pub] 20181009

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV15-26865A MZ0 CEP Register

Background: The complement system activation and regulation have been linked to post-transplant pathologies including chronic antibody mediated rejection (cAMR) and the recurrence of IgA nephropathy (ReIgAN) but distinct mechanisms remain to be elucidated. Methods: In this retrospective single center study, the outcome of kidney transplantation was studied in 150 patients with late histological diagnosis to be either cAMR or ReIgAN, 14 stable kidney grafts at 3 months and finally 11 patients with native kidney IgAN nephropathy. To study a role of complement cascade and regulation in cAMR and ReIgAN, the RNA was extracted from available frozen kidney biopsy samples and using RT-qPCR transcripts of 11 target genes along with clinical data were determined and compared with stable grafts at 3 months protocol biopsies or IgAN native kidney nephropathy. Immunohistologically, CD46 (MCP), and C5 proteins were stained in biopsies. Results: Interestingly, there were no differences in kidney graft survival between cAMR and ReIgAN since transplantation. cAMR was associated with significantly higher intragraft transcripts of C3, CD59, and C1-INH as compared to ReIgAN (p < 0.05). When compared to normal stable grafts, cAMR grafts exhibited higher C3, CD55, CD59, CFH, CFI, and C1-INH (p < 0.01). Moreover, ReIgAN was associated with the increase of CD46, CD55, CD59 (p < 0.01), and CFI (p < 0.05) transcripts compared with native kidney IgAN. Rapid progression of cAMR (failure at 2 years after biopsy) was observed in patients with lower intrarenal CD55 expression (AUC 0.77, 78.6% sensitivity, and 72.7 specificity). There was highly significant association of several complement intrarenal transcripts and the degree of CKD regardless the diagnosis; C3, CD55, CFH, CFI, and C1-INH expressions positively correlated with eGFR (for all p < 0.001). Neither the low mRNA transcripts nor the high mRNA transcripts biopsies were associated with distinct trend in MCP or C5 proteins staining. Conclusions: The intrarenal complement system transcripts are upregulated in progressively deteriorated kidney allografts.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045171
003      
CZ-PrNML
005      
20201016161945.0
007      
ta
008      
200109s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2018.02310 $2 doi
035    __
$a (PubMed)30356754
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Cernoch, Marek $u Transplant Laboratory, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.
245    10
$a Intrarenal Complement System Transcripts in Chronic Antibody-Mediated Rejection and Recurrent IgA Nephropathy in Kidney Transplantation / $c M. Cernoch, P. Hruba, M. Kollar, P. Mrazova, L. Stranavova, A. Lodererova, E. Honsova, O. Viklicky,
520    9_
$a Background: The complement system activation and regulation have been linked to post-transplant pathologies including chronic antibody mediated rejection (cAMR) and the recurrence of IgA nephropathy (ReIgAN) but distinct mechanisms remain to be elucidated. Methods: In this retrospective single center study, the outcome of kidney transplantation was studied in 150 patients with late histological diagnosis to be either cAMR or ReIgAN, 14 stable kidney grafts at 3 months and finally 11 patients with native kidney IgAN nephropathy. To study a role of complement cascade and regulation in cAMR and ReIgAN, the RNA was extracted from available frozen kidney biopsy samples and using RT-qPCR transcripts of 11 target genes along with clinical data were determined and compared with stable grafts at 3 months protocol biopsies or IgAN native kidney nephropathy. Immunohistologically, CD46 (MCP), and C5 proteins were stained in biopsies. Results: Interestingly, there were no differences in kidney graft survival between cAMR and ReIgAN since transplantation. cAMR was associated with significantly higher intragraft transcripts of C3, CD59, and C1-INH as compared to ReIgAN (p < 0.05). When compared to normal stable grafts, cAMR grafts exhibited higher C3, CD55, CD59, CFH, CFI, and C1-INH (p < 0.01). Moreover, ReIgAN was associated with the increase of CD46, CD55, CD59 (p < 0.01), and CFI (p < 0.05) transcripts compared with native kidney IgAN. Rapid progression of cAMR (failure at 2 years after biopsy) was observed in patients with lower intrarenal CD55 expression (AUC 0.77, 78.6% sensitivity, and 72.7 specificity). There was highly significant association of several complement intrarenal transcripts and the degree of CKD regardless the diagnosis; C3, CD55, CFH, CFI, and C1-INH expressions positively correlated with eGFR (for all p < 0.001). Neither the low mRNA transcripts nor the high mRNA transcripts biopsies were associated with distinct trend in MCP or C5 proteins staining. Conclusions: The intrarenal complement system transcripts are upregulated in progressively deteriorated kidney allografts.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alografty $7 D064591
650    _2
$a buněčná cytotoxicita závislá na protilátkách $7 D000920
650    _2
$a biopsie $7 D001706
650    _2
$a dítě $7 D002648
650    _2
$a chronická nemoc $7 D002908
650    _2
$a komplement $x genetika $x imunologie $7 D003165
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a IgA nefropatie $x diagnóza $x etiologie $x terapie $7 D005922
650    _2
$a rejekce štěpu $x genetika $x imunologie $7 D006084
650    _2
$a přežívání štěpu $x genetika $x imunologie $7 D006085
650    _2
$a lidé $7 D006801
650    _2
$a isoprotilátky $x imunologie $7 D007518
650    _2
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ROC křivka $7 D012372
650    _2
$a recidiva $7 D012008
650    _2
$a genetická transkripce $7 D014158
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hruba, Petra $u Transplant Laboratory, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Kollar, Marek $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Mrazova, Petra $u Transplant Laboratory, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Stranavova, Lucia $u Transplant Laboratory, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Lodererova, Alena $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Honsova, Eva $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Viklicky, Ondrej $u Transplant Laboratory, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia. Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czechia.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 9, č. - (2018), s. 2310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30356754 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20201016161943 $b ABA008
999    __
$a ok $b bmc $g 1483440 $s 1083844
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 2310 $e 20181009 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a NV15-26865A $p MZ0
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...